Vol.

No.

September 10, 2021Sep 10, 2021

DOWNLOAD THE PDF

NCI requests $7.8B for FY2023 to increase R01 paylines to 13th percentile

Cover Story

NCI

NCI requests $7.8B for FY2023 to increase R01 paylines to 13th percentile

By Matthew Bin Han Ong

NCI is asking for an appropriation of $7.8 billion for fiscal year 2023—about $800 million above the House’s FY22 proposed budget for NCI.

Conversation with The Cancer Letter

As his center wins comprehensive (again), Carlos Arteaga tells us how NCI’s standards have evolved

By Paul Goldberg

Cancer History Project Conversation with The Cancer Letter Free

How 1960s activism shaped the movement that resulted in the DOD breast cancer program

By Alexandria Carolan

Free In the Archives

Advocacy: Shaping cancer care through survivorship—and politics

Clinical Trials & Tribulations

Converting Cox hazard ratios with Cox-TEL to improve interpretation of drug efficacy in checkpoint inhibitor trials

By Yu Shyr

In Brief

Elvan ‘Ellie’ Daniels named SVP of extramural discovery science at ACS

David Frank named director of the Division of Hematology at Emory

Gregory Lesinski named associate director for basic research at Emory

Yamilé Molina named associate director for community outreach and engagement at University of Illinois Cancer Center

Robert Mannel, Bradley Monk, Carol Aghajanian named to new positions on the GOG Foundation’s board of directors

Benjamin Ellingson receives $665,000 Idea award to improve brain tumor imaging

ASTRO urges CMS to reconsider $300M in Medicare cuts for radiation therapy

Thyme Care and Clover Health form strategic partnership to deliver personalized support to cancer patients

Clinical Roundup

Vaping prevention is critical as teens head back to school during pandemic

Yale Cancer Center study shows stem-like T cells could aid immunotherapy in cancer treatment

Miami Cancer Institute study shows ablative MR-guided radiation therapy may prolong survival for patients with inoperable pancreatic cancer

Drugs & Targets

Active ingredient hypericin receives FDA orphan drug designation for T-cell lymphoma

Science 37, Foundation Medicine collaborate on interventional home-based clinical trials in oncology

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues